
UN trade agency says it faces ‘painful' cuts as countries navigate tariffs
GENEVA -- The United Nations trade and development agency, tasked with helping developing countries access the global economy, faces 'painful' cuts as part of broader reforms prompted by a decline in global donor funding, its secretary general said.
Rebeca Grynspan told Reuters she was concerned that UNCTAD's work will be hampered while demand for its services grows, as countries seek information on the impact of sweeping tariffs imposed by U.S. President Donald Trump.
For UNCTAD's 2026 budget, Grynspan said she and her team had proposed cutting 70 posts, out of a total of about 500.
'This is painful. There's no way to disguise this ... we haven't cut that number of posts ever in one budget,' she said.
'It really will constrain the organization and the things that we can do.'
UN agencies like UNCTAD are having to cut costs amid a financial crisis triggered in part by the U.S., which has provided nearly a quarter of the world body's funding, and longer term liquidity problems.
'What worries me the most is the possibility to respond to countries in their needs fast enough,' Grynspan said.
Grynspan, who is part of the task force on broader UN80 reforms to improve efficiency and cut costs at the UN, said she was involved in discussions on how to better divide tasks among the UN's development agencies through collaboration.
The UN Secretariat, the global body's executive arm, is preparing to slash its US$3.7 billion budget by 20%. About 75 agencies and departments faced a June 13 deadline to propose budget cuts. The UN in Geneva is proposing leaving the historic Palais Wilson, which houses its human rights office.
The final decision on UNCTAD's proposed budget will be made by the UN Secretariat and member states in September.
Reporting by Olivia Le Poidevin; Editing by Aidan Lewis, Reuters
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Canada Standard
an hour ago
- Canada Standard
Is Mark Carney turning his back on climate action?
The G7 summit in Alberta, hosted by Prime Minister Mark Carney, has ended with only passing mention of fighting climate change, including a statement on wildfires that is silent on the pressing need to reduce greenhouse gas emissions. This is puzzling. Canadians didn't opt for Conservative Pierre Poilievre, considered by some to be an oil and gas industry mouthpiece, in the last federal election. Instead, voters gave Carney's Liberals a minority government. Carney was the United Nations Special Envoy on Climate Action and Finance and was behind the UN-backed Net-Zero Banking Alliance, so some Canadians might have assumed he'd prioritize climate action if he won the election. Instead, Carney has described developing fossil fuel infrastructure as "pragmatic." But it's unclear how a country grappling with abysmal air quality due to wildfires fuelled by global warming will benefit from further global fossil fuel development and its related emissions. Read more: Wildfire smoke can harm your brain, not just your lungs Canada is warming faster than most of the globe. Its leaders should be laser-focused on mitigating climate change by reducing fossil fuel use to the greatest extent possible, as soon as possible. This decades-long understanding of how to approach climate action has been repeatedly explained by experts and is well known to governments globally. Canada's prime minister was once one of those experts. Carney now has a tremendous opportunity to lead by steering Canada in a clean direction. Canada is at the forefront of clean technology, with numerous business opportunities emerging, particularly in areas like circular economy international trade. These opportunities not only support Canada's commitment to meeting its Paris Agreement targets but also help expand and diversify its global trade. Canada already has exemplar eco-industrial parks - co-operative businesses located on a common property that focus on reducing environmental impact through resource efficiency, waste reduction and sharing resources. Such industrial communities are in Halifax and in Delta, B.C. They represent significant investment opportunities. Vacant urban land could be revitalized and existing industrial parks could boost their economic output and circular trade by building stronger partnerships to share resources, reduce waste and cut emissions. Read more: A sustainable, circular economy could counter Trump's tariffs while strengthening international trade Canada would benefit economically and environmentally by building on existing expertise and expanding successful sustainability strategies to achieve economic, environmental and social goals. But by continuing to invest in fossil fuels, Canada misses out on opportunities to diversify trade and boost economic competitiveness. Real diversification makes Canada less vulnerable to economic shocks, like the ones caused by the tariffs imposed by United States President Donald Trump. Fossil fuel reliance increases exposure to global economic risks, but shifting to cleaner products and services reduces climate risks and expands Canada's global trade options. China's economic rise is partly a result of this strategy. That's seemingly why Trump is so fixated on China. China today is a serious competitor to the U.S. after making smart trade and economic decisions and forging its own path, disregarding American pressure to remain a mere follower. Investing in its huge Belt and Road Initiative, China also aligned itself with the United Nations Sustainable Development Goals. It's building diplomatic bridges with many Belt and Road countries in southeast Asia as Trump's America alienates its partners, pulling out of the Paris Agreement and cutting foreign aid. As another one of the America's mistreated partners, Canada was poised to forge its own path under Carney. Instead, Carney is supporting American oil and gas by encouraging Canadian pipeline projects. Canadian oil and gas is a concentrated industry controlled by a wealthy few, primarily Americans. More pipelines would therefore mean more sales of fossil fuels to other countries, with the beneficiaries mostly American. Fossil fuel investments reduce Canada's diversification because the resources used to further these projects could go elsewhere - toward clean diversification. With almost unlimited clean economy options across many sectors, clean diversification would broaden Canada's economic and trade portfolios and reduce American control. Read more: Why Canada's Strong Borders Act is as troublesome as Donald Trump's travel bans This is International Business 101, and would make the Canadian economy more competitive through innovation, while reducing the country's climate risk. California, often targeted by Trump for its policies, has been a leader in clean innovation, making its economy the envy of the world. Read more: California is planning floating wind farms offshore to boost its power supply - here's how they work My recent research shows that clear, decisive choices like those made in California will be key to Canada's future success. Canada must make choices aligned with goals - a core principle of strategic management. My research also suggests Canada must restructure its energy industry to focus on renewable energy innovation while reducing fossil fuel reliance. Increased renewable energy innovation, as seen in patent numbers, leads to higher GDP. Contrary to common beliefs, pollution taxes boost the economy in combination with clean innovation. But when the government supports both the fossil fuel industry and clean industries, it hinders Canada's transition to a cleaner future. Do Canadian taxpayers truly want to keep funding an outdated, polluting industry that benefits a wealthy few, or invest in clean industries that boost Canada's economy, create better jobs and protect the environment? To differentiate Canada from the United States, it would make sense to choose the latter. Carney should consider refraining from pushing for the fast-tracking of polluting projects. If he doesn't, Canada will become more uncompetitive and vulnerable, trapped by the fossil fuel industry. Read more: Mark Carney wants to make Canada an energy superpower - but what will be sacrificed for that goal? Carney's support for pipelines may have stemmed from Alberta Premier Danielle Smith's implicit support for Alberta sovereignty. She made veiled threats to Canada at a critical juncture, when Trump was making repeated assertions about annexing Canada. Alberta didn't vote for Carney. But Canadians who care about mitigating climate change did. Banks that felt pressure to at least recognize sustainable finance during the Joe Biden administration joined Carney's Net-Zero Banking Alliance. But as soon as Trump came to power a second time and walked away from the Paris Agreement, many American banks abandoned the alliance. Canadian banks followed suit, and Carney remarkably missed another moment to show Canadian leadership by stopping their exit. In fact, Carney seems to have abandoned his own organization to appease Trump as the president made multiple 51st state threats. The prime minister had the chance to differentiate Canada and demonstrate his own leadership. Instead, he seems to have easily turned his back on his principles under pressure from Trump.


National Post
3 hours ago
- National Post
Terry Glavin: Trump didn't belong at G7
Article content The Israeli operation was put in motion against the backdrop of the UN's International Atomic Energy Agency finding last week of 'serious and growing concerns' that Iran has not been straight with IAEA inspectors since at least 2019. Iran has repeatedly failed to demonstrate that it wasn't diverting nuclear material for a clandestine nuclear-bomb program, the IAEA reported. Article content As for Russia's war on Ukraine, that global catastrophe barely got a look-in. There was no G7 statement dealing with Vladimir Putin's war or his threats to Europe, and the big controversy about that was merely about whether the Trump administration had scuttled a draft statement or whether Carney's government hadn't even bothered to formulate a statement that Trump, whose pleadings on behalf of Russian strongman Vladimir Putin go back several years, could be persuaded to sign. Article content Trump left halfway through the summit anyway, ostensibly to focus on the Israel-Iran conflict. Ukrainian president Volodymyr Zelenskyy didn't bother to stick around either, and it was just as well. All Ukraine got was a handful of passing mentions in Carney's 'chair's summary' to the effect that the G7 supports the idea of 'a strong and sovereign Ukraine' and that Russia should match Ukraine's commitment to an unconditional ceasefire. As if to soften the blow, Carney pledged a further $4.3 billion in military and reconstruction aid to Ukraine this week, along with more sanctions targeting Russia's 'shadow fleet' of dodgy oil tankers. Article content And then there was this: 'G7 Leaders expressed support for President Trump's efforts to achieve a just and lasting peace in Ukraine.' Article content This is a sentence that stoops below obsequiousness to outright self-abasement. Article content Trump's 'efforts' in this matter have consisted mainly in allowing himself to be conscripted as Vladimir Putin's propaganda conduit, grossly exaggerating the Biden administration's contribution to Ukraine, boasting about his good relations with Putin and generally sabotaging Ukraine's efforts to defend itself in the bloodiest war in Europe since the Nazi era. Trump also says the war would never have happened had he been president instead of Joe Biden. Article content Trump's hubris got the better of him again on Monday, with Carney standing at his side. Trump repeated his wish that the G7 had not expelled Putin in 2014, a move he attributed to former prime minister Justin Trudeau and former president Barack Obama. Trump also repeated his nonsense suggestion that Putin would not have gone to war if Russia had not been expelled from the G8 (for good measure, Trump suggested on Monday that China should be added to the G7's membership). Article content In fact, it was former Prime Minister Stephen Harper who led the charge to expel Russia, more than a year before Trudeau came to power, and Russia's ejection occurred after Putin invaded Donbas and annexed Ukraine's Crimean peninsula. Article content Trump also claimed, again, that the U.S. had spent $350 billion on Ukraine's war effort. This is roughly three times the true amount, and significantly less than the funds the Europeans and Canada have contributed in military, humanitarian and military aid. Just over the past two months, the Kiel Institute's Ukraine support tracker shows that Europe has advanced $23 billion in aid to Ukraine, and the U.S. has contributed nothing. Article content To date, the sum total of Trump's 'peace talks' consists of a minerals profit-sharing arrangement with Ukraine intended to recover the cost of U.S. contributions to date, no U.S. security guarantees or commitment for future military aid, and 'Crimea,' the main prize in Putin's 2014 invasion, 'will stay with Russia.' Article content Adding to Ukraine's humiliation: While the heads of government of Canada, the U.S., France, Germany, Italy, Japan and the United Kingdom were meeting in Kananaskis, Russia launched its deadliest drone attack on Kyiv this year, killing at least 18 people and wounding 151. Article content


Globe and Mail
3 hours ago
- Globe and Mail
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the Vaccines unit, generic competition for some drugs and broader economic pressure. Let's discuss these factors in detail to understand how to play GSK's stock amid the recent price increase. GSK Specialty Medicines Unit on a Strong Footing GSK is witnessing increased sales growth of its Specialty Medicines unit, particularly reflecting successful new launches in Oncology and long-acting HIV medicines. Sales are rising in all areas, HIV, Immunology/Respiratory as well as Oncology. Sales of the Specialty Medicines unit rose 19% in 2024, driven by double-digit growth in all therapy areas. The positive trend continues in 2025 with sales rising 17% in the first quarter of 2025. In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient demand and contributing to top-line growth. In 2025, the company expects sales in the Specialty Medicines segment to rise in a low double-digit percentage at CER, despite the impact from the Inflation Reduction Act or IRA. Specialty Medicines, which now accounts for around 40% of GSK's sales, is expected to be more than 50% of GSK's total revenue by 2031. GSK's Promising Pipeline GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. GSK's pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection ('UTI') were approved in the United States in the first quarter of 2025. Its blockbuster drug Nucala was approved for treating chronic obstructive pulmonary disease or COPD, its fifth indication, in May 2025. Regulatory applications seeking approval of the Blenrep combination for relapsed/refractory multiple myeloma and depemokimab for two indications (chronic rhinosinusitis with nasal polyps or CRSwNP and asthma with type II inflammation) are under review in the United States and some other countries. FDA decisions on all these filings are expected in 2025. Blenrep combinations were approved in the United Kingdom and Japan in April/May 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and Nucala for COPD are already approved in the United States. GSK's Vaccine Sales Slowing Down GSK's first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix. U.S. sales of Shingrix declined 21% in the first quarter of 2025 due to lower demand as a result of challenges in activating harder-to-reach consumers. Arexvy's global sales declined 57% in the first quarter. Revised recommendations for RSV vaccinations issued in June 2024 by the U.S. Advisory Committee on Immunization Practices (ACIP) have been hurting sales of Arexvy from the second half of 2024 in the United States. In June, the ACIP recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. A challenging macro environment in China and potential for changes in vaccination policies in the United States are expected to hurt Vaccine sales in the near term. In 2025, the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK's Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since May. GSK Stock Outperforms Industry, Sector and S&P GSK's stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.63 on a forward 12-month basis, lower than 15.63 for the industry. The stock also trades below its 5-year mean of 10.25. The stock is much cheaper than several other large drugmakers like Eli Lilly LLY, Novo Nordisk NVO, AbbVie ABBV and AstraZeneca. GSK Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $4.26 to $4.42 per share for 2025 and from $4.71 to $4.82 per share for 2026 over the past 60 days. GSK's Estimates Stay Invested in GSK Stock GSK has its share of problems. Competitive pressure on HIV and respiratory drugs has risen. The dolutegravir HIV franchise patent expires in the 2028-2029 period, and U.S. vaccine sales are slowing down. In 2025, GSK also expects a negative sales impact of £400-500 million due to the impact of the IRA Medicare Part D redesign. However, the company is consistently growing its sales and profits, mainly driven by its Specialty Medicines segment. For the five-year period till 2026, GSK expects to record more than 7% sales growth while core operating profit is expected to increase more than 11% on a CAGR basis. In this period, Specialty Medicines is expected to rise in the low-to-mid teens percentage while General Medicines is expected to rise by a low single-digit percentage. The growth in Specialty Medicines and improvement in General Medicines are making up for a slowdown in the Vaccines unit. The company also resolved the vast majority of Zantac litigations in 2024, which had long been an overhang on the stock. GSK believes it is well-positioned to navigate and mitigate the potential financial impact of tariffs on pharmaceutical imports through supply chain and increased productivity initiatives We suggest investors who own this Zacks Rank #3 (Hold) stock stay invested for now, considering steady sales and profit improvement in the coming years. Consistently rising estimates also reflect analysts' optimistic outlook for future growth in profits. Buying the stock at its present cheap valuation can prove prudent for long-term investors who are interested in buying blue-chip companies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report